

Please Note: Supplemental rebate offers for the May 2024 TOP\$ cycle are due within four weeks of this formal request for offers. Monday, 5 February 2024 is the due date for all supplemental rebate offers for the current TOP\$ cycle.

Monday, 8 January 2024

Dear Pharmaceutical Manufacturer:

In May 2024, the Pharmacy & Therapeutics (P&T) Committees of the states participating in the Magellan Medicaid Administration, Inc. multi-state initiative, TOP\$SM -- The Optimal PDL \$olutionSM, will review the products and therapeutic classes on the attached list and available for download at:

<https://www1.magellanrx.com/preferred-drug-list-programs/manufacturing-hub/top-the-optimal-pdl-solution/>

The states currently participating in TOP\$SM are **Connecticut, Idaho, Louisiana, Maryland, Nebraska, Washington, and Wisconsin**. On behalf of those states and in preparation for this review, Magellan Medicaid invites you to submit offers for your products in these therapeutic classes.

Louisiana and Maryland will review new products in those therapeutic classes reviewed in November 2023 that came to market and listed by First DataBank between 27 September 2023 and 5 January 2024.*

*Note: Connecticut, Idaho, Nebraska, Washington and Wisconsin only review new products in conjunction with their scheduled therapeutic class reviews.

Please note that as of this official request for offers, the final review schedule of therapeutic classes is subject to change. Please reference the TOP\$ online presence at <https://www1.magellanrx.com/preferred-drug-list-programs/manufacturing-hub/top-the-optimal-pdl-solution/> for any updates to the therapeutic classes.

Please continue to check each state's web site, or the Magellan Rx web site (<https://www1.magellanrx.com/preferred-drug-list-programs/manufacturing-hub/top-the-optimal-pdl-solution/>), for updates to the P&T Committee meeting review schedule.

The calculation used to determine the supplemental unit rebate amount is Guaranteed Net Unit Price (GNUP) based on Wholesale Acquisition Cost (WAC). No other pricing calculation type will be accepted for TOP\$SM.

The GNUP is calculated as:

GNUP = WAC Price per Unit - Federal Unit Rebate Amount - Supplemental Rebate Amount.

The GNUP represents the value that will determine your supplemental rebate amount each quarter, along with the WAC price and Federal URA in effect for that quarter, throughout the term (1 year) of the contract. The GNUP is one of the values that you are to provide on the Offer Form

(along with your WAC and Federal URA), and is the value that will appear on your contract as the contract price.

All offers are to be submitted via the Secure FTP site (<https://secureftp.providersynergies.com/>) using the TOP\$SM Offer Form attached or available for download at:


<https://www1.magellanrx.com/preferred-drug-list-programs/manufacturing-hub/top-the-optimal-pdl-solution/>

The format and layout of the TOP\$SM Offer Form allows for the import of your Offer Form information through an automated process. Therefore, it is critical that you use only the current TOP\$SM Offer Form attached or obtain the current Offer Form from our web site at the location referenced above. Please provide the information requested and in the format requested according to the instructions on the form. The re-use or modification of an Offer Form from a previous TOP\$SM meeting, or using an Offer Form intended for an individual state will render your Offer Form unrecognizable by our systems.

The following information is provided to assist you in completing and submitting your Offer Form in addition to the information provided on the Offer Form itself:

To download the Excel TOP\$SM Offer Form click on the above link, or copy that link into your browser.

If you are using Internet Explorer as your web browser, after clicking on the TOP\$SM Offer Form link, you should see:



Click on the “Save” button to transfer the Excel TOP\$SM Offer Form to your PC. The TOP\$SM Offer Form file MUST reside on YOUR computer in order for you to complete it. It cannot be completed “on-line” or from within our web site.

Do not change the column heading names, add or delete columns or rows, or modify any formatting on the Offer Form. Doing so may render your Offer Form information unrecognizable by our systems, and will require that your Offer Form be returned to you for correction and re-submission.

Once you have completed entering all requested information, and prior to submitting the Offer Form to our Secure FTP site, please save and re-name the Offer Form file as *TOP\$ [Your Company] Offer Form.xls*. For example "*TOP\$ XYZ Corporation Offer Form.xls*". Please limit your company's name to no more than 15 characters. Using any other naming convention or saving the file as a type other than .xls will render your Offer Form unrecognizable by our systems.

OPERATION CHANGE: On 04 April 2008, Provider Synergies sent an email to manufacturers notifying them of some operational changes. Please note, at the direction of the TOP\$ states, we will no longer accept Supplemental Rebate offers that are submitted after the due date indicated in this solicitation. We may, after the deadline, request clarification and/or modification of some offers but, other than those submitted pursuant to such requests, **offers received after the deadline will not be considered and will not be presented to the TOP\$ states.**

PLEASE NOTE: There is a character limit of 220 characters (including spaces) for the Notes column of the Offer Form. Please keep all Notes under that limit. Otherwise, your offer will be rejected by our system and the offer will need to be revised and resubmitted.

All best and final supplemental rebate offers must be submitted to the Secure FTP site (<https://secureftp.providersynergies.com/>) by:

5:00 p.m. Eastern Time on Monday, 5 February 2024.

Offers received after 5:00 p.m. Eastern Time on Monday, 5 February 2024, via our Secure FTP site will result in the exclusion of such offers from this review.

A confirmation of receipt is automatically generated and will be sent to the e-mail address designated on the Preparer Information tab of each Offer Form. This e-mail is sent when the file is downloaded from the Secure FTP site to our internal servers, *not* when you upload the file to the Secure FTP site. Therefore, please allow at least 4 hours from the time of submission to the Secure FTP site for the generation of the confirmation of receipt to occur.

For detailed written instructions on how to access and upload your Offer Form to the Secure FTP site, please contact Cole Anderson (andersonc2@magellanhealth.com) (cole.anderson@primetherapeutics.com). Requests for new user names and passwords, or requests to re-set existing user names and passwords should be submitted via e-mail to Cole Anderson (andersonc2@magellanhealth.com) (cole.anderson@primetherapeutics.com). User names and passwords will not be provided over the telephone.

Clinical data pertinent to the products for these reviews may be submitted to Provider Synergies in electronic format only to the attention of Maryam Tabatabai, PharmD via e-mail (mtabatabai@magellanhealth.com).

The PDL status and contract values awarded by the states participating in TOP\$SM on the basis of this review supersede and replace any existing contracts associated with those products currently in effect for those states. Supplemental rebates for those products selected by each state for its Preferred Drug List will begin to accrue **01 July 2023**. The term of the contract is one year.

If you did not receive the attachments included in this e-mail notification, all documents may be obtained from our web site at:

<https://www1.magellanrx.com/preferred-drug-list-programs/manufacturing-hub/top-the-optimal-pdl-solution/>

Thanks,
-Cole

Cole Anderson

Health Informatics Analyst, PDL Analytics
Magellan Rx Management, a Prime Therapeutics company

Magellan e-mail: andersonc2@magellanhealth.com

Prime e-mail: cole.anderson@primetherapeutics.com



I am no longer using this email address. As Prime and Magellan Rx come together to create a next-generation pharmacy solutions enterprise, my email address has changed. My new address is cole.anderson@primetherapeutics.com. Please use this address for all future communications. I look forward to hearing from you.

CONFIDENTIALITY NOTICE: The information contained in this communication may be confidential, and is intended only for the use of the recipients named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited. If you have received this communication in error, please return it to the sender immediately and delete the original message and any copy of it from your computer system. If you have any questions concerning this message, please contact the sender.